DDInter62 DDInter899
Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Ambrisentan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluconazole
Ambrisentan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Ambrisentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Ambrisentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ambrisentan {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Ambrisentan {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Ambrisentan may cause a minor interaction that can limit clinical effects when taken with Fluconazole
Ambrisentan may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ambrisentan may lead to a major life threatening interaction when taken with Leflunomide
Ambrisentan may lead to a major life threatening interaction when taken with Teriflunomide